Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573533 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01573533: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01573533 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01573533, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional therapies.
Primary Outcome
The amount of protein in excreted urine measured by grams per day (g/day). Remission status defined by the following criteria at 12 months: * Complete Remission - Proteinuria \< 0.5 g/day * Partial Remission - Improvement in proteinuria by \> 50% and to a level between 0.5-3.5g/day * Incomplete Remission - Improvement in proteinuria equal to or \>50%, but residual proteinuria still \>3.5g/day
Interventions
- BIOLOGICAL Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-11-15 |
| Phase | Phase 2 |
What the finished NCT01573533 record still lists
NCT01573533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT01573533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01573533 about?
NCT01573533 is a clinical study titled "A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS". The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional therapies.
What is the current status of trial NCT01573533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-10. Estimated completion is 2018-11-15.
What interventions are being tested in trial NCT01573533?
The interventions under investigation include: Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01573533?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01573533's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia